123 related articles for article (PubMed ID: 10026917)
1. Gene marking and gene therapy in multiple myeloma.
Gahrton G; Björkstrand B; Dilber MS; Sundman-Engberg B; Ljungman P; Smith CI
Adv Exp Med Biol; 1998; 451():493-7. PubMed ID: 10026917
[No Abstract] [Full Text] [Related]
2. Suicide gene therapy for plasma cell tumors.
Dilber MS; Abedi MR; Björkstrand B; Christensson B; Gahrton G; Xanthopoulos KG; Smith CI
Blood; 1996 Sep; 88(6):2192-200. PubMed ID: 8822939
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system.
Culver KW; Van Gilder J; Link CJ; Carlstrom T; Buroker T; Yuh W; Koch K; Schabold K; Doornbas S; Wetjen B
Hum Gene Ther; 1994 Mar; 5(3):343-79. PubMed ID: 8018748
[TBL] [Abstract][Full Text] [Related]
4. Construction of MDR1 vectors for gene therapy.
Sugimoto Y; Gottesman MM; Pastan I; Tsuruo T
Methods Enzymol; 1998; 292():523-37. PubMed ID: 9711580
[No Abstract] [Full Text] [Related]
5. Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma.
Goebel EA; Davidson BL; Graham SM; Kern JA
Otolaryngol Head Neck Surg; 1998 Oct; 119(4):331-6. PubMed ID: 9781985
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and immunologic effects of in vivo retrovirus-mediated gene transfer of the herpes simplex-thymidine kinase gene into solid tumors.
Culver KW; Moorman DW; Muldoon RR; Paulsen RM; Lamsam JL; Walling HW; Link CJ
Cold Spring Harb Symp Quant Biol; 1994; 59():685-90. PubMed ID: 7587131
[No Abstract] [Full Text] [Related]
7. Adenovirus-mediated ex vivo immunogene and in vivo combination gene therapy strategies induce a systemic anti-tumor immune defense in the mouse B16 melanoma model.
Bonnekoh B; Greenhalgh DA; Chen SH; Bickenbach J; Block A; Rich SS; Krieg T; Woo SL; Roop DR
Adv Exp Med Biol; 1998; 451():335-43. PubMed ID: 10026893
[No Abstract] [Full Text] [Related]
8. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection.
Tapscott SJ; Miller AD; Olson JM; Berger MS; Groudine M; Spence AM
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):8185-9. PubMed ID: 8058777
[TBL] [Abstract][Full Text] [Related]
9. Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells.
Vile RG; Diaz RM; Castleden S; Chong H
Biochem Soc Trans; 1997 May; 25(2):717-22. PubMed ID: 9191190
[No Abstract] [Full Text] [Related]
10. Gene therapy for glioblastoma [correction of gliobestome] multiform: in vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir.
Stockhammer G; Brotchi J; Leblanc R; Bernstein M; Schackert G; Weber F; Ostertag C; Mulder NH; Mellstedt H; Seiler R; Yonekawa Y; Twerdy K; Kostron H; De Witte O; Lambermont M; Velu T; Laneuville P; Villemure JG; Rutka JT; Warnke P; Laseur M; Mooij JJ; Boëthius J; Mariani L; Gianella-Borradori A
J Mol Med (Berl); 1997 Apr; 75(4):300-4. PubMed ID: 9151217
[No Abstract] [Full Text] [Related]
11. Experimental study of the RV-HSV-TK/GCV suicide gene therapy system in gastric cancer.
Tang Q; Zhang D; Wan M; Jin L
Cancer Biother Radiopharm; 2007 Dec; 22(6):755-61. PubMed ID: 18158766
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of establishment of hepatic metastasis in mice by combination gene therapy using both herpes simplex virus-thymidine kinase and granulocyte macrophage-colony stimulating factor genes in murine colon cancer.
Hayashi S; Emi N; Yokoyama I; Namii Y; Uchida K; Takagi H
Cancer Gene Ther; 1997; 4(6):339-44. PubMed ID: 9408603
[TBL] [Abstract][Full Text] [Related]
13. Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir.
Howard BD; Boenicke L; Schniewind B; Henne-Bruns D; Kalthoff H
Cancer Gene Ther; 2000 Jun; 7(6):927-38. PubMed ID: 10880025
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal gene therapy for malignant leptomeningeal neoplasia.
Ram Z; Walbridge S; Oshiro EM; Viola JJ; Chiang Y; Mueller SN; Blaese RM; Oldfield EH
Cancer Res; 1994 Apr; 54(8):2141-5. PubMed ID: 8174120
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system.
Raffel C; Culver K; Kohn D; Nelson M; Siegel S; Gillis F; Link CJ; Villablanca JG; Anderson WF
Hum Gene Ther; 1994 Jul; 5(7):863-90. PubMed ID: 7981311
[No Abstract] [Full Text] [Related]
16. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer.
Hwang HC; Smythe WR; Elshami AA; Kucharczuk JC; Amin KM; Williams JP; Litzky LA; Kaiser LR; Albelda SM
Am J Respir Cell Mol Biol; 1995 Jul; 13(1):7-16. PubMed ID: 7598939
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy of chondrosarcoma using retrovirus vectors encoding the herpes simplex virus thymidine kinase gene.
Seto M; Wakabayashi H; Yamazaki T; Sonoda J; Shinto Y; Uchida A
Int J Oncol; 1999 Jun; 14(6):1137-41. PubMed ID: 10339670
[TBL] [Abstract][Full Text] [Related]
18. Ablation of tumor cells in vivo by direct injection of HSV-thymidine kinase retroviral vector and ganciclovir therapy.
Howard BD; Kalthoff H; Fong TC
Ann N Y Acad Sci; 1999 Jun; 880():352-65. PubMed ID: 10415879
[TBL] [Abstract][Full Text] [Related]
19. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase.
Rogers RP; Ge JQ; Holley-Guthrie E; Hoganson DK; Comstock KE; Olsen JC; Kenney S
Hum Gene Ther; 1996 Dec; 7(18):2235-45. PubMed ID: 8953314
[TBL] [Abstract][Full Text] [Related]
20. Another mechanism causing the bystander effect besides the gap junction's role during the glioma gene therapy with HSV-TK/GCV system.
Du L; Bai S; Whittle IR; He L
Adv Exp Med Biol; 1998; 451():133-8. PubMed ID: 10026862
[No Abstract] [Full Text] [Related]
[Next] [New Search]
